Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Clinical Trials

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

Phase 4

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Corticotropin 80Unit/Ml Repository Injection

First Posted Date: 2017-09-19

Last Posted Date: 2021-01-28

Lead Sponsor: Toyos Clinic

Target Recruit Count: 19

Registration Number: NCT03287635

Locations: 🇺🇸
Toyos Clinic, Nashville, Tennessee, United States

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

Phase 4

Terminated

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Placebo
Drug: Acthar Gel

First Posted Date: 2017-04-24

Last Posted Date: 2021-07-12

Lead Sponsor: Mallinckrodt ARD LLC

Target Recruit Count: 35

Registration Number: NCT03126760

Locations: 🇺🇸
Neurology Associates, P. A., Maitland, Florida, United States
🇺🇸
Wayne State University (WSU) - Multiple Sclerosis Treatment and Clinical Research Center (MS Center), Detroit, Michigan, United States
🇺🇸
Neurology Center of San Antonio, San Antonio, Texas, United States

and more 19 locations

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

Phase 4

Conditions: Rheumatoid Arthritis

Interventions: Drug: H.P. Acthar gel

First Posted Date: 2017-03-17

Last Posted Date: 2017-03-17

Lead Sponsor: Iraj Sabahi Research Inc.

Target Recruit Count: 30

Registration Number: NCT03082573

Locations: 🇺🇸
Iraj Sabahi Research Inc, Turlock, California, United States

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Acthar
Drug: Placebo

First Posted Date: 2017-03-03

Last Posted Date: 2020-10-14

Lead Sponsor: Mallinckrodt

Target Recruit Count: 143

Registration Number: NCT03068754

Locations: 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 66 locations

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

Phase 4

Conditions: Uveitis, Posterior
Vasculitis Retinal

Interventions: Drug: H.P. ACTHAR GEL

First Posted Date: 2017-03-01

Last Posted Date: 2019-09-12

Lead Sponsor: Ocular Immunology and Uveitis Foundation

Target Recruit Count: 40

Registration Number: NCT03066869

Locations: 🇺🇸
Ocular Immunology & Uveitis Foundation, Waltham, Massachusetts, United States

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

Suspended

Conditions: Nephrotic Syndrome

Interventions: Drug: Acthar Gel and Tacrolimus

First Posted Date: 2017-02-03

Last Posted Date: 2021-02-17

Lead Sponsor: Southeast Renal Research Institute

Registration Number: NCT03042637

Locations: 🇺🇸
Nephronet, Chattanooga, Tennessee, United States

Adrenocorticotropic Hormone in Membranous Nephropathy

Phase 4

Completed

Conditions: Membranous Nephropathy

Interventions: Drug: ACTHar

First Posted Date: 2017-01-20

Last Posted Date: 2022-08-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 5

Registration Number: NCT03025828

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses

Phase 4

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: ACTHar

First Posted Date: 2017-01-13

Last Posted Date: 2024-05-16

Lead Sponsor: University of Chicago

Target Recruit Count: 5

Registration Number: NCT03021317

Availability Study of ACTH to Treat Children SRNS/SDNS

Not Applicable

Conditions: Proteinuria

Interventions: Drug: ACTH

First Posted Date: 2016-11-23

Last Posted Date: 2016-11-23

Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 42

Registration Number: NCT02972346

Locations: 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

Phase 4

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Acthar Gel
Drug: Placebo Gel

First Posted Date: 2016-11-03

Last Posted Date: 2020-08-20

Lead Sponsor: Mallinckrodt

Target Recruit Count: 172

Registration Number: NCT02953821

Locations: 🇺🇸
Center for Rheumatology Immunology and Arthritis, Fort Lauderdale, Florida, United States
🇺🇸
Sun Research Institute, San Antonio, Texas, United States
🇲🇽
IBIOMED Research Unit Aguascalientes, Aguascalientes, Mexico

and more 36 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy